ASML Holding NV
Change company Symbol lookup
Select an option...
ASML ASML Holding NV
FUN Cedar Fair LP
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Growth
Based in Netherlands
Company profile

ASML Holding N.V. is a holding company. The Company is a manufacturer of chip-making equipment. The Company is engaged in the development, production, marketing, selling and servicing of semiconductor equipment systems, consisting of lithography systems. The Company's products include systems, and installed base products and services. The Company's principal operations are in the Netherlands, the United States and Asia. The Company offers TWINSCAN systems, equipped with lithography system with a mercury lamp as light source (i-line), Krypton Fluoride (KrF) and Argon Fluoride (ArF) light sources for 300 millimeter processing wafers for manufacturing environments for which imaging at a small resolution is required. TWINSCAN systems also include immersion lithography systems (TWINSCAN immersion systems). The Company also offers NXE systems, which are equipped with extreme ultraviolet (EUV) light source technology. The Company offers YieldStar, a wafer metrology system.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$366.34
Day's Change
-0.40 (-0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
370.91
Day's Low
359.93
Volume
(Average)
Volume:
912,176

10-day average volume:
933,051
912,176

Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications

10:00 am ET July 20, 2020 (Globe Newswire) Print

Vyriad, Inc. announced today the dosing of the first patient in a Phase 2 clinical trial to evaluate its investigational oncolytic virus Voyager-V1 in combination with the PD-1 inhibitor Libtayo (cemiplimab) in four difficult-to-treat or refractory advanced stage cancers. Libtayo is being jointly developed and commercialized by Regeneron and Sanofi under a global collaboration agreement.

The open-label study will enroll up to an estimated 152 patients with non-small cell lung cancer or melanoma who have progressed on checkpoint inhibitor treatment and patients with hepatocellular carcinoma or endometrial cancer. The study will evaluate overall patient responses to the treatment, as well as safety, tolerability, pharmacodynamic and pharmacokinetic data. For additional information about the study, please visit www.clinicaltrials.gov (search identifier NCT04291105).

Voyager-V1 is an engineered vesicular stomatitis virus programmed to target, infect and kill cancer cells, while activating immune system responses that may enhance the restoration of antitumor T cell response by Libtayo.

"We are optimistic that this therapeutic combination will meaningfully increase the treatment responses of cancer patients with high unmet clinical needs," said Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. "We are pleased the study has commenced and we look forward to the results."

"The promise of cancer immunotherapies has yet to be fulfilled as evidenced by their limited effectiveness in many patient groups," said Steven Powell, M.D., a medical oncologist who is the study's principal investigator at Sanford Health, which treated the first patient in the study. "We're excited to evaluate this therapy, which combines a systemically active oncolytic with an effective immunotherapy. We hope that this combination approach may turn cold tumors hot and facilitate clinically meaningful anti-cancer immune responses in multiple cancer types."

Libtayo was invented by Regeneron using the company's proprietary VelocImmune technology which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence. Our lead platforms, derived from either vesicular stomatitis virus or measles virus (VSV), are being evaluated in ongoing Phase 2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have entered into a broad strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo (cemiplimab) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota. For more information, visit www.vyriad.com.

Contacts:

Media Relations   Investor Relations
David Walsh       Barb Duckett
(651) 503-8248    (507) 289-0944
dwalsh@vyriad.com bduckett@vyriad.com

https://ml.globenewswire.com/media/f223eeaa-9d9c-40b8-b106-e8561011ff98/small/vyriad-logo-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.